Should I Buy BIO.B? BIO.B 2026 Analysis

Should You Buy Bio Rad Laboratories Inc (BIO.B) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

295.050

1 Day change

52 Week Range

343.850

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is below the key pivot (301.20) with bearish momentum signals and no proprietary buy signals today.
Downside risk dominates near-term: pattern-based forecast skews slightly negative over 1D/1M, and options open-interest positioning is put-heavy.
Only turns attractive for an impatient buyer if it quickly reclaims ~301–312 (pivot/R1) with improving momentum; otherwise odds favor chop-to-down toward 290/283 support.

Technical Analysis

Trend/Momentum: MACD histogram (-1.6) below zero and only modestly contracting → bearish momentum still present.
RSI(6) ~42.9 → weak/neutral, not oversold enough to signal a strong mean-reversion buy.
Moving averages converging → no clear uptrend; suggests consolidation with a bearish tilt.
Levels: Pivot 301.20 (key reclaim level). Resistance R1 312.34, R2 319.23. Support S1 290.06, S2 283.17.
Current pre-market ~295.05 sits below pivot and closer to support → risk of a support test before any sustained upside.
Intellectia signals: AI Stock Picker = no signal today; SwingMax = no recent signal → no strong tactical “must-buy” trigger.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest: Put/Call OI ratio 2.26 (puts 659 vs calls 291) → positioning leans defensive/bearish.
Volume: Put/Call volume ratio 0.01 (puts 1 vs calls 98) → today’s flow is call-skewed, but total put volume is extremely low, so confidence in bullish flow is limited.
Volatility: IV ~~36.6% with IV percentile ~42 and very low IV rank (~~6.5) → options are not priced for extreme moves; sentiment signal mainly comes from put-heavy OI rather than elevated fear.
Activity: today’s volume vs 30D avg is elevated (220), but absolute volume is still small (99 contracts).

Technical Summary

Sell

Buy

Positive Catalysts

- Hedge fund activity: “Hedge Funds are Buying” with a sharp quarter-over-quarter increase in buying activity (supportive medium-term signal).
- Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-17 after hours (can reset the narrative if results/guide improve).
- If price reclaims 301–312 (pivot to R1), technicals could flip from bearish consolidation to a more constructive breakout setup.

Neutral/Negative Catalysts

- Technical setup is not supportive for an immediate buy: trading below pivot with bearish MACD.
- Options positioning: put-heavy open interest (2.26 OI PCR) suggests investors are still hedging/downside-protecting.
- No news-driven catalysts in the past week to justify an urgent upside re-rating.
- Pattern-based forward drift is slightly negative (next day/month probabilities skew to mild downside).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $653.0M, +0.50% YoY → essentially flat growth.
Profitability: Net income -$341.9M (down -152.34% YoY) and EPS -12.7 (down -154.41% YoY) → major deterioration versus last year.
Margins: Gross margin 52.5%, down ~4.16% YoY → weakening operating quality in the quarter.
Takeaway: fundamentals (recent quarter) do not support an aggressive buy-the-dip entry without a clear technical reversal or upcoming earnings turnaround.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so a recent trend assessment isn’t available.
Wall Street pro view (what would typically be supportive): durable life-science tools franchise and potential rebound if profitability normalizes.
Wall Street con view (currently most relevant given the data): sharp earnings deterioration and margin pressure raise skepticism until results stabilize.

0 Analyst Rating

Wall Street analysts forecast BIO.B stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO.B is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 295.050

Low

Averages

High

Current: 295.050

Low

Averages

High

Wells Fargo

Brandon Couillard

Hold

Maintains

$320 → $270

AI Analysis

2025-04-17

Reason

Wells Fargo

Brandon Couillard

Price Target

$320 → $270

AI Analysis

2025-04-17

Maintains

Hold

Reason

Wells Fargo

Brandon Couillard

Hold

Maintains

$360 → $345

2025-02-12

Reason

Wells Fargo

Brandon Couillard

Price Target

$360 → $345

2025-02-12

Maintains

Hold

Reason

BIO.B Should I Buy

BIO.B Should I Buy

Should You Buy Bio Rad Laboratories Inc (BIO.B) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch